April 09, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany – 9 April, 2026 – Boehringer Ingelheim today announced a clinical trial collaboration with BioNTech to evaluate a novel immuno‑oncology combination in extensive‑stage small cell lung cancer (ES-SCLC), one of the most aggressive and underserved forms of cancer. Under the agreement, BioNTech will supply pumitamig (BNT327/BMS‑986545), a PD‑L1/VEGF‑A […]

April 09, 2026 07:30 ET  | Source: Smith & Nephew UK Ltd Results from the first-ever randomized control trial for the REGENETEN Implant in partial–thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated

April 09, 2026 06:00 ET  | Source: Zymeworks Inc. • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional

April 09, 2026 04:00 ET  | Source: Boehringer Ingelheim Limited •    Ecuador aims to become one of the first rabies free countries in Latin America.•    Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. •    Boehringer Ingelheim announces critical support to the project at the international One Health Summit

The New Beauty-Led Hydration Brand Debuts Globally April 08, 2026 09:01 ET  | Source: iHerb Holdings, Inc. IRVINE, Calif., April 08, 2026 (GLOBE NEWSWIRE) — iHerb, one of the world’s largest online retailers specializing in health and wellness, today announced an exclusive international partnership with k2o, founded by Kylie Jenner. Through this partnership, iHerb will soon bring k2o’s drink

April 07, 2026 18:54 ET  | Source: AliveCor Inc. MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, today announced the regulatory registration of its Kardia™ 12L electrocardiogram (ECG) System powered by KAI™ 12L AI technology in Vietnam, marking an important step toward expanding AI-enabled cardiac diagnostics across Southeast Asia.

Rigorous training and certification gives clinicians a validated pathway to AI-enabled cardiac POCUS proficiency April 07, 2026 11:24 ET  | Source: Inteleos, Inc. ROCKVILLE, Md. and BORDEAUX, France, April 07, 2026 (GLOBE NEWSWIRE) — HeartFocus, the AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, today announced a partnership with Inteleos® through its Point-of-Care Ultrasound (POCUS) Certification

April 07, 2026 09:00 ET  | Source: Saladax Biomedical, Inc. Bethlehem, PA, April 07, 2026 (GLOBE NEWSWIRE) — Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, today announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that support clinicians in optimizing patient outcomes.

AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality April 07, 2026 07:00 ET  | Source: Fortrea Holdings Inc Highlights: DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial

April 06, 2026 09:00 ET  | Source: Egg Medical, Inc. MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) — Egg Medical announces the launch of EggNest™ Complete Flex, a groundbreaking advancement in radiation protection that enables clinicians to safely work apron-free or with ultralight lead aprons—without the need for construction, structural modifications or procedural downtime. The first live case

April 02, 2026 07:10 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing

April 02, 2026 07:01 ET  | Source: Adagene Inc. Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for

April 02, 2026 07:00 ET  | Source: Adagene Inc. Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR)

April 01, 2026 17:00 ET  | Source: Adagene Inc. In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months  4% overall discontinuation rate, no dose limiting toxicities,

April 01, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026.